Condensed Statements of Operations - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
|
| Revenue: | ||||
| License and milestone fees | $ 1,710 | $ 1,710 | $ 302 | |
| Collaborative revenue | 730 | $ 1,125 | 2,093 | 1,802 |
| Clinical compound revenue | 0 | 159 | ||
| Total revenue | 2,440 | 1,125 | 3,803 | 2,263 |
| Operating expenses: | ||||
| Research and development | 5,584 | 6,208 | 13,653 | 11,609 |
| General and administrative | 1,865 | 1,520 | 5,609 | 4,390 |
| Total operating expenses | 7,449 | 7,728 | 19,262 | 15,999 |
| Operating loss | (5,009) | (6,603) | (15,459) | (13,736) |
| Interest income | 22 | 26 | 49 | 104 |
| Loss before benefit from income taxes | (4,987) | (6,577) | (15,410) | (13,632) |
| Benefit from income taxes | 200 | 32 | 250 | 59 |
| Net loss | $ (4,787) | $ (6,545) | $ (15,160) | $ (13,573) |
| Net loss per share -Basic and Diluted | $ (0.19) | $ (0.29) | $ (0.64) | $ (0.67) |
| Weighted average shares: | ||||
| Basic and Diluted | 25,545,164 | 22,713,040 | 23,737,443 | 20,351,005 |
| X | ||||||||||
- Definition Amount reclassified from collaborative revenue to clinical compound revenue. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized in the period from the revenue deferred upon initiation of the Maruishi license agreement. The amount recognized is based on the amount of research and development costs incurred during the period as a percentage of total such costs expected to be incurred to fulfill the research and development deliverable. Also includes a portion of the revenue recognized from nonsubstantive milestones. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized upon entering into a license agreement with a collaborator combined with cash received upon achievement of a defined milestone by the collaborator. No definition available.
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net amount of nonoperating interest income (expense). No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|
| X | ||||||||||
- References No definition available.
|